This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Rheumatology  • Immunologic Disorders  • Rheumatoid Arthritis  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Infliximab is a chimeric mouse-human monoclonal antibody targeting tumor necrosis factor . It is approved for the treatment of refractory rheumatoid arthritis (RA), Crohn disease, ankylosing spondylitis, and psoriatic arthritis. Infliximab usually is well tolerated and has a good safety profile; only rare cases of severe adverse effects, including cardiac failure or mycobacterial infections, have been reported.¹ A frequently observed and striking laboratory finding is the development of antinuclear antibodies, usually without clinical lupuslike symptoms.²

Report of a Case

A 51-year-old woman with a long history (>10 years) of seropositive RA experienced a progression of the disease despite maintenance therapy with nonsteroidal antirheumatic medication and methotrexate. Therefore, she was treated with infliximab (Remicade; Centocor, Malvern, Pa), 5 mg/kg of body weight, and she experienced an almost complete response. However, following the 13th infusion, the patient developed a few erythematous indurated plaques (without epidermal changes) on her face and upper chest (Figure). She . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION
Stefan W. Schneider, MD; Sonja Staender, MD; Bernhard Schlüter, MD; Thomas A. Luger, MD; Gisela Bonsmann, MD